News Center
-91.jpg)
All
2024
2023
2022
2021
2020
-
LM-108 Receives Fast Track Designations for Cancer Treatments from US FDA2024-02-21
Learn More
-
FDA Granted LM-108 Orphan Drug Designations for Cancer Treatments2023-12-18
Learn More
-
CDE Granted LM-302 Breakthrough Therapy Designation for Claudin 18.2 positive GC/GEJ2023-11-23
Learn More
-
LaNova Medicines and LegoChem evaluate novel first-in-class antibody drug conjugate candidate2023-04-26
Learn More
-
LaNova Medicines Announces the IND Approval of LM-101 by NMPAShanghai November 15th, 2022 – LaNova Medicines Ltd. announced that the investigational new drug (IND) of LM-101, an anti-SIRPα monoclonal antibody, has been approved by China NMPA.
2022-11-15Learn More
-
LaNova Medicines Announces the IND Approval of LM-305, a GPRC5D-targeting ADC Drug by NMPA
Shanghai November 10th, 2022 – LaNova Medicines Ltd. announces that the investigational new drug (IND) of LM-305, an ADC drug targeting GPRC5D, has been approved by China NMPA.
2022-11-10Learn More